Results 191 to 200 of about 3,768,017 (341)
Molecular Oncology, EarlyView.Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen +9 more
wiley +1 more source
Interventions to Enable or Improve Evidence-Informed Decision Making in Public Health and Preventive Medicine: A Scoping Review. [PDF]
AJPM FocusGroot E, Pelley J, Boylan AM, Nunan D.
europepmc +1 more source
Crude lymphocyte levels: Can the past accelerate the future in preventive medicine? [PDF]
Am J Hematol, 2023 Zidar DA.
europepmc +1 more source
Insights into a long life without cancer: The case of the bowhead whale
Molecular Oncology, EarlyView.Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley +1 more source
Herpes Zoster Vaccine Awareness and Uptake Among Older Adults in Saudi Arabia: Insights for Public Health, Preventive Medicine, and Primary Care Practice. [PDF]
J Gen Fam MedAldhawyan AF +9 more
europepmc +1 more source
Molecular Oncology, EarlyView.Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source
American Journal of Preventive Medicine
American Journal of Medicine, 2018 A. Ramírez, Guadalupe X Ayala
semanticscholar +1 more source
Molecular cancer prevention: Intercepting disease
Molecular Oncology, EarlyView.Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco +2 more
wiley +1 more source